STING1 and ovarian carcinoma: Recently, a poly(ADP-ribose) polymerase (PARP) inhibitor Olaparib was shown to trigger robust STING-dependent antitumor immune responses in breast cancer type 1 (BRCA1)-deficient ovarian cancer, which induces robust adaptive and innate antitumor immune responses.